The Hindu Business Line : InterVein Labs, D2L Pharma sign MoU

The city-based InterVein Laboratories and the Bangalore-based D2L Pharma Research Solutions have signed a memorandum of understanding for providing one-stop solution to the global clinical research industry.

InterVein, which commenced its operations in 2006, caters to clinical trial samples only and is one of the few central laboratories in India providing such services to clinical research.

On the other hand, D2L Pharma is engaged in site management and consulting services, according to a release here. The two would collaborate on providing their competencies in clinical investigations and site management services.

This partnership will enable them to jointly provide an integrated platform for pharmaceutical companies, to enable them to move the promising drug candidates to the marketplace faster, Ms Devina Bhardwaj, CEO, InterVein Laboratories and Dr K. Sashi Kiran, Founder and Managing Director, D2L Pharma Research Solutions, said.

More Stories on : Alliances & Joint Ventures | Pharmaceuticals | Gujarat

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
India Cements buys ship

Xenitis launches sub-Rs 20,000 bike

HUL closes buyback of shares

Aurobindo bags Rs 70 cr order from NACO

Tatas acquire General Chemical of US for $1 b

Tata Chemicals acquisition timed well

Deccan Aviation, Kingfisher Air merger ratio fixed at 3:7

Puravankara plans to invest Rs 1,000 cr

Manaksia to set up steel facility in Georgia

InterVein Labs, D2L Pharma sign MoU

MRPL scholarship for students

Williamson Magor to target Tier II, III cities for land buy

GMR to raise Rs 250 cr thru rights issue

ONGC may give up 2 CBM blocks in western region

Daimler targets to sell 3,000 Merc Benz this year

Mundra Port handles 20.3 mt cargo in 9 mths; net at Rs 122 cr